9AM - 5PM EST | 3PM - 11PM CEST

8:00 am Online Registration & Virtual Coffee Networking

Synopsis

Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

8:45 am Chair’s Opening Remarks

  • Amel Karaa Assistant Professor , Harvard Medical School

Clinical Development & Current Trials

9:00 am Keynote Presentation: Targeting Therapeutic Molecules to Mitochondria to Treat Ischaemia-Reperfusion (IR) Injury in Heart Attack, Stroke & Organ Transplantation

  • Mike Murphy Principal Investigator, MRC Mitochondrial Biology Unit, University of Cambridge

Synopsis

• Discuss strategies to target small molecules to mitochondria
• Explore examples of targeting cardiac IR injury with complex I active molecules
• Discover examples of targeting mitochondrial succinate metabolism in heart attack, stroke and organ transplantation

9:30 am A Mitochondrial Etiology of Common Diseases

  • Douglas Wallace Michael & Charles Barnett Endowed Chair | Director | Professor, Pediatric Mitochondrial Medicine & Metabolic Disease | Center for Mitochondrial & Epigenomic Medicine | University of Pennsylvania

Synopsis

• Examine how primary mitochondrial disease manifestations imply that common diseases may involve impaired mitochondrial function
• Evaluate how the complexity of the genetics of the common diseases is due to the distribution of mitochondrial genes across the mitochondrial and nuclear DNAs
• Explore human mitochondrial genetic variation including and how it’s been shaped by ancient regional natural selection and how this variation can result in differential sensitivity to modern environmental challenges
• Discover therapies that prove beneficial for primary mitochondrial diseases and how they may be useful for common disorders

10:00 am Meaningful Pleiotropic Pharmacology for Truly Insidious Pleiotropic Diseases

  • John Geisler Founder & Chief Scientific Officer, Mitochon Pharmaceuticals

Synopsis

• Examine how MP101 & MP201 lowers mitochondrial calcium overload, mTOR and ROSs that drive apoptosis
• Observe how MP101 & MP201 increase cognitive factors: cAMP, CREB and BDNF that pushes repair
• Analyze how MP101 & MP201 wake up compensatory mechanisms prosurvival as an oral once-per-day brain penetrating small molecule

10:30 am Virtual Speed Networking

Synopsis

Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

11:00 am Showcasing Breakthrough Mitochondrial Science

  • Pinchas Cohen Dean & Co-Founder, USC School of Gerontology & CohBar Inc.

Synopsis

  • Mitochondrial Genomics as a Platform for Novel Micropeptide Drug Discovery
  • MOTS-c Analogues for Metabolic Diseases – Precision Medicine and Beyond
  • CohBar’s Pipeline: New Solutions for Diseases of Aging

 

11:30 am Clinical Stage Molecules Targeting Mitochondrial Mechanisms & Mitochondrial Dysfunction for Metabolic Disorders

  • Sophie Bozec Senior Vice President, R&D Pharmacology & Co-founder, POXEL

Synopsis

• Understand mitochondrial dysfunction in metabolic diseases
• Examine how Imeglimin; a new first in class acts on Mitochondrial bioenergetics as a new treatment for Type 2 diabetes
• Explore PXL065 a stabilized single stereoisomer of pioglitazone acts on a mitochondrial target to enable treatment of NASH
• Observe PXL770, a direct AMPK activator ameliorates mitochondrial dysfunction for the treatment of NASH

12:00 pm Panel Discussion: Recognize the Financial Difficulty of Developing Drugs for Targeting Mitochondria & Moving Drugs to the Next Phase

  • Natalie Ohana Yivgi Co-Founder & Chief Executive Officer, Minovia Therapeutics
  • Jake Chen Professor of Biomedical Engineering, University of Alabama at Birmingham
  • Mehmood Khan Chief Executive Officer, Life Biosciences
  • Magali Taiel Chief Medical Officer, GenSight Biologics
  • Nicholas Hertz Chief Scientific Officer, Mitokinin
  • Pinchas Cohen Dean & Co-Founder, USC School of Gerontology & CohBar Inc.

Synopsis

• Explore the challenges of funding development
• Learn how drug developers can inspire and attract companies to invest in their novel development and pipeline
• Discover how can the industry come together to overcome the paucity of funding

12:45 pm Networking Lunch

Synopsis

Grab lunch from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

1:45 pm Mitochondrial Augmentation Therapy (MAT): Harnessing the power of mitochondria for therapeutic purposes

Synopsis

• Examine Mitochondrial Augmentation Therapy (MAT)
• Preclinical and clinical review of the multi-systemic effect of MAT in mitochondrial diseases
• Advance the research of MAT to address far-reaching applications

Clinical Trial Design

2:15 pm Lessons Learned in the Development of Therapies for Mitochondrial Disease

Synopsis

• Explore important learnings from over a decade of mitochondrial disease drug development
• Discuss lessons learned including elements of clinical study design and regulatory strategy
• Examine how these conversations are applicable to all therapeutic modalities

Gene Therapy & Editing

2:45 pm Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy (LHON)

Synopsis

• Examine LHON and its main clinical aspects
• Late-stage development of Lumevoq Gene Therapy
• Discuss regulatory pathways
• Outline key learnings Lumevoq gene therapy

3:15 pm Netwoking Break

Synopsis

• Live Demo in Virtual Exhibition Hall
• 1-1 Meetings

Technology & Innovation: Accelerating High Tech Involvement in Daily Practice

3:45 pm Advances in Biophysical Approaches to Studying Drug Interactions with Mitochondrial Membranes & Membrane Proteins

  • Nathan Alder Associate Professor, University of Connecticut

Synopsis

• Study how biological membranes and membrane protein complexes are key targets for drug development despite the many experimental challenges they present
• Investigate how new advances in model membrane systems allow unprecedented experimental access to traditionally recalcitrant samples
• Examine innovations in structural and functional characterization of mitochondrial membrane proteins that are rendering new insights into drug interactions
• See how these technological advances have strong potential to help elucidate molecular mechanisms of action and assist in the design of next-generation analogs for mitochondria-targeted compounds

4:15 pm Chair’s Closing Remarks

  • Amel Karaa Assistant Professor , Harvard Medical School

4:30 pm End of Day Two & Summit